Stéphane Cattan
Centre Hospitalier Universitaire de Lille · 134 works · 7,734 citations · h-index 30
Top works
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- Long-Term Evolution of Disease Behavior of Crohn's Disease
- Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
- Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer
- Impact of cessation of smoking on the course of ulcerative colitis
- Crohn's disease clinical course and severity in obese patients
- Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
- Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
- Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score
- Dramatic Increase in Incidence of Ulcerative Colitis and Crohn's Disease (1988–2011): A Population-Based Study of French Adolescents
- Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301)
- Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM)
- High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn’s Disease
- Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: A large multicenter AGEO study
- Iliac artery dissection in α1-antitrypsin deficiency
- Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial
- Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study
- Hepatocellular carcinoma screening in patients with compensated hepatitis C virus (HCV)-related cirrhosis aware of their HCV status improves survival: A modeling approach
- Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
- KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.